This discovery has overturned the traditional belief that "the fate of stem cells is solely determined by transcriptional and epigenetic regulation.

Recently, the international top journal "Cell Stem Cell" published online a groundbreaking study led by the Novo Nordisk Foundation Stem Cell Medicine Center (reNEW) at the University of Copenhagen.

This discovery has broken through the limitations of the traditional "single-target" treatment strategy, providing a completely new paradigm for cell therapy in complex neurodevelopmental disorders such as autism spectrum disorder (ASD).

The first clinical trial (jRCT2090220384) using allogeneic IPSC-differentiated dopaminergic neural progenitor cells (iPSC-DANs) for transplantation to treat patients with Parkinson's disease was conducted, and only tacrolimus was used for immunotherapy.

In the current era of rapid advancements in medical technology, pluripotent stem cell therapy, with its tremendous potential and continuous breakthroughs, has become the core focus of the global medical field.

In the current era of rapid advancements in medical technology, pluripotent stem cell therapy, with its tremendous potential and continuous breakthroughs, has become the core focus of the global medical field.

In the current era of rapid advancements in medical technology, pluripotent stem cell therapy, with its tremendous potential and continuous breakthroughs, has become the core focus of the global medical field.

In the current era of rapid advancements in medical technology, pluripotent stem cell therapy, with its tremendous potential and continuous breakthroughs, has become the core focus of the global medical field.